Department of Internal Medicine, Division of Endocrinology, Faculty of Medicine, Süleyman Demirel University, Isparta, Turkey
Department of Medical Genetics, Faculty of Medicine, Süleyman Demirel University, Isparta, Turkey
Turk J Med Sci. 2021 Aug 30;51(4):2081-2086. doi: 10.3906/sag-2010-245.
BACKGROUND/AIM: miRNAs control various biological functions, such as cell proliferation, differentiation, signaling pathways, apoptosis and metabolism. Recently, it has been shown that there is a relationship between changes in miRNA expression and the development of acromegaly. Studies are needed to identify new disease-specific miRNAs. The aim of the current study is to evaluate plasma miR-29c-3p, miR-31-5p and miR-18a-5p steady-state levels in acromegaly. Another aim is to investigate whether there is a difference in the levels of these miRNAs in patients with inadequate control and controlled acromegaly with somatostatin analog (SSA) therapy. These miRNAs targeting the IGF-1 gene were determined by in silico estimation.
The study included 30 healthy controls (HC) and 20 patients with acromegaly. Anterior pituitary functions and disease activities of patients with acromegaly were evaluated at the time of study. The miR-29c-3p, miR-31-5p and miR-18a-5p levels were measured using quantitative real-time PCR (RT-qPCR).
The expression level of miR-29c-3p was significantly lower in patients with acromegaly compared to the HC group (p < 0.001). This downregulation was more pronounced in patients with inadequately controlled acromegaly than in patients with acromegaly controlled with somatostatin analogues (SSA) therapy (p = 0.016). Univariate logistic regression analysis results showed that down regulation of miR-29c-3p expression increases the risk of developing acromegaly [OR (95% Cl) = 1.605 (1.142-2.257), p = 0.006]. There was no significant difference between the groups in terms of miR-31-5p and miR-18a-5p expression levels (p = 0.375 and p = 0.649, respectively).
Plasma miR-29c-3p expression level is downregulated in patients with acromegaly, and this is more pronounced in patients with inadequate control.
背景/目的：miRNAs 控制着各种生物功能，如细胞增殖、分化、信号通路、细胞凋亡和代谢。最近，已经表明 miRNA 表达的变化与肢端肥大症的发展有关。需要研究来识别新的疾病特异性 miRNAs。本研究的目的是评估肢端肥大症患者血浆 miR-29c-3p、miR-31-5p 和 miR-18a-5p 的稳态水平。另一个目的是研究这些 miRNA 在生长激素分泌瘤患者中，在未经充分控制和使用生长抑素类似物 (SSA) 治疗得到控制的情况下，其水平是否存在差异。这些针对 IGF-1 基因的 miRNA 是通过计算机预测来确定的。
该研究纳入了 30 名健康对照者（HC）和 20 名肢端肥大症患者。在研究时评估了患者的前垂体功能和疾病活动。使用定量实时 PCR (RT-qPCR) 测量 miR-29c-3p、miR-31-5p 和 miR-18a-5p 的水平。
与 HC 组相比，肢端肥大症患者的 miR-29c-3p 表达水平显著降低（p<0.001）。在未经充分控制的肢端肥大症患者中，这种下调更为明显，而在使用生长抑素类似物（SSA）治疗得到控制的肢端肥大症患者中则不明显（p=0.016）。单变量逻辑回归分析结果表明，miR-29c-3p 表达下调增加了肢端肥大症的发病风险[OR（95%Cl）=1.605（1.142-2.257），p=0.006]。miR-31-5p 和 miR-18a-5p 表达水平在各组之间无显著差异（p=0.375 和 p=0.649）。
肢端肥大症患者的血浆 miR-29c-3p 表达水平下调，在未经充分控制的患者中更为明显。
